글로벌 천포창 Vulgaris 시장 – 2030년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

글로벌 천포창 Vulgaris 시장 – 2030년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • Jul 2023
  • Global
  • 350 Pages
  • 테이블 수: 383
  • 그림 수: 66

Global Pemphigus Vulgaris Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Chart Image 677.32 2023 2030
Diagram 예측 기간
2024 –2030
Diagram 시장 규모(기준 연도)
백만 달러
Diagram 시장 규모(예측 연도)
미국 달러 677.32
Diagram 연평균 성장률
%
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>진단 및 치료(진단 및 치료), 인구 유형(소아과, 성인 및 노인과), 최종 사용자(병원, 전문 클리닉, 연구소 및 기타), 유통 채널(병원 약국, 소매 약국 및 온라인 약국)별 글로벌 천포창 시장 - 2030년까지의 업계 동향 및 예측.

천포창 Vulgaris 시장

천포창 Vulgaris 시장 분석 및 통찰력

디지털 건강 기술의 사용 및 채택이 증가함에 따라 시장 수요가 증가했습니다. 주요 시장 참여자는 이 중요한 기간 동안 다양한 제품 승인 및 가용성에 중점을 둡니다. 또한 개선되고 진보된 의료 시설의 증가도 시장 수요 증가에 기여합니다.

천포창 Vulgaris 시장천포창 Vulgaris 시장

면역 기반 피부 질환의 증가로 인해 예측 연도에 시장이 성장할 것으로 예상됩니다. 다양한 NGO가 천포창으로 고통받는 환자를 지원하는 것도 시장 성장을 촉진할 것으로 예상됩니다. 이와 함께 제조업체는 시장에서 R&D 활동과 승인에 참여하고 있습니다. 그러나 치료 절차 및 약물 승인과 관련된 엄격한 규제 지침은 시장 성장을 제한할 것으로 예상됩니다. 개인화된 의학에 대한 수요 증가는 시장에 기회를 제공할 것으로 예상됩니다. 모든 시설을 갖춘 더 나은 품질의 의료 서비스에 대한 수요 증가는 시장 성장을 촉진할 것으로 예상됩니다. 그러나 치료와 관련된 부작용은 시장 성장에 도전할 것으로 예상됩니다.

Data Bridge Market Research는 글로벌 천포창 시장이 2030년까지 6억 7,732만 달러에 도달할 것으로 예상되며, 예측 기간 동안 CAGR은 8.2%입니다. 진단 및 치료는 전 세계 인구 중 천포창 환자 수가 증가함에 따라 시장에서 가장 큰 유형 세그먼트를 차지합니다. 이 시장 보고서는 또한 가격 분석, 특허 분석 및 기술 발전에 대한 심층적인 내용을 다룹니다.

보고서 메트릭

세부

예측 기간

2023년부터 2030년까지

기준 연도

2022

역사적 연도

2021 (2015-2020까지 사용자 정의 가능)

양적 단위

매출은 백만, 볼륨은 단위, 가격은 USD로 표시

다루는 세그먼트

진단 및 치료(Diagnosis and Treatment), 인구 유형(소아, 성인 및 노인), 최종 사용자(병원, 전문 클리닉, 연구소 및 기타), 유통 채널(병원 약국, 소매 약국 및 온라인 약국)

적용 국가

미국, 캐나다, 멕시코, 독일, 프랑스, ​​영국, 이탈리아, 러시아, 스페인, 네덜란드, 스위스, 벨기에, 터키, 유럽의 나머지 지역, 중국, 일본, 인도, 호주, 한국, 싱가포르, 말레이시아, 태국, 인도네시아, 필리핀, 아시아 태평양의 나머지 지역, 남아프리카, 사우디 아라비아, UAE, 이스라엘, 이집트, 중동 및 아프리카의 나머지 지역, 브라질, 아르헨티나, 남미의 나머지 지역

시장 참여자 포함

Sanofi, Regeneron Pharmaceuticals Inc., Fresenius Kabi AG, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., RAKSHIT DRUGS PVT. LTD, F. Hoffmann-La Roche Ltd, Pfizer Inc., Celltrion Healthcare Co., Ltd., AbbVie Inc., Novartis AG, Amgen Inc., Merck & Co., Inc., AstraZeneca, Teva Pharmaceutical Industries Ltd, Lilly, Zydus Group, GSK plc 등이 있습니다.

글로벌 천포창 Vulgaris 시장 정의

천포창이라는 희귀하고 만성적인 자가면역 질환은 피부와 점막에 물집이 생기는 것이 특징입니다. 천포창이라고 알려진 자가면역성 물집 질환의 가장 전형적인 변형으로 여겨집니다. 천포창에서 면역 체계는 피부 세포의 부착에 필요한 단백질인 데스모글레인을 표적으로 하는 항체를 의도치 않게 생성합니다. 이 항체 공격으로 인해 물집이 생기고 피부층이 분리됩니다. 신체 어디에나 물집이 생길 수 있지만 입, 목, 두피, 얼굴, 가슴, 사타구니, 겨드랑이가 물집이 생기는 가장 일반적인 위치입니다. 질병에 대한 인식이 높아짐에 따라 시장 성장이 촉진될 것으로 예상됩니다.

천포창의 정확한 기원은 알려지지 않았지만 유전적 소인과 환경적 자극이 합쳐져서 생기는 것으로 생각됩니다. 민감한 사람의 경우 특정 약물, 감염 또는 자외선 노출과 같은 특정한 것들이 질병을 유발하거나 악화시킬 수 있습니다. 그러나 엄격한 규제 지침이 시장 성장을 억제할 것으로 예상됩니다.

 

글로벌 천포창 Vulgaris 시장 역학

이 섹션에서는 시장 동인, 기회, 제약 및 과제를 이해하는 것을 다룹니다. 이 모든 내용은 아래에서 자세히 설명합니다.  

운전자

  • 천포창 심상성 증상에 대한 새로운 치료 옵션

천포창은 소수의 사람들에게 영향을 미치는 만성 면역 체계 장애입니다. 그 결과 피부와 입에 물집이 생깁니다. 심각한 경우 약물로 통제할 수 있지만, 각질 세포 사이의 접착 분자를 표적으로 삼는 자가항체는 천포창이라고 알려진 지속적이고 심각한 자가면역 수포성 질환을 일으킵니다. 이 질환은 평균 2~3년 동안 관리해야 합니다.

전신성 글루코코르티코이드로 치료하면 천포창 심상성 환자의 생명을 구할 수 있지만 치명적인 부작용이 있을 수도 있습니다. 전신성 글루코코르티코스테로이드를 제공해야 할 필요성이 생기기 전에 천포창 심상성 환자 한 명은 콜린 유사 약물인 메스티논(피리도스티그민 브로마이드), 이무란(아자티오프린) 및 국소 코르티코스테로이드 젤로 거의 5년 동안 치료를 받았습니다.

따라서 천포창에 대한 새로운 치료 옵션이나 접근법이 시장 성장을 촉진할 것으로 예상됩니다.

  • 영향을 받은 환자들을 위한 NGO의 지원이 확대되고 있습니다.

수많은 비정부 기구(NGO)와 환자 지원 그룹은 지원, 자원 및 옹호를 제공하여 천포창 환자를 돕기 위해 많은 노력을 기울이고 있습니다. 천포창에 초점을 맞춘 지역 또는 지역 지원 조직은 특정 지역이나 국가에 존재할 수 있습니다. 이러한 조직은 지역 사회별 옹호 활동, 동료 지원 및 지역 자원을 제공할 수 있습니다.

따라서 천포창 환자를 위한 NGO의 지원이 커지면서 시장 성장이 촉진될 것으로 예상됩니다.

천포창 Vulgaris 시장

기회

  • 치료 관리를 위한 디지털 건강 기술

디지털 건강 기술은 천포창 환자의 치료 및 관리에 상당한 영향을 미칠 수 있는 잠재력이 있습니다. 피부과 의사 및 기타 의료 전문가는 원격 진료를 통해 환자가 가상으로 상담할 수 있으므로 직접 방문할 필요가 없습니다. 이는 이동성 문제나 제한된 접근으로 인해 의료 시설에 가는 데 어려움이 있는 천포창 환자에게 특히 도움이 될 수 있습니다. 정기 검진, 약물 모니터링 및 후속 진료는 원격 진료를 통해 용이하게 할 수 있으므로 치료의 연속성과 치료 프로그램의 즉각적인 수정이 가능합니다.

수많은 모바일 앱과 온라인 도구는 천포창 환자에게 도움이 되는 리소스가 될 수 있습니다. 이러한 플랫폼은 자가 모니터링 도구, 약물 알림 및 교육 리소스를 제공할 수 있습니다. 환자는 증상, 약물 및 질병 진행 상황을 추적할 수 있으므로 자신의 치료에 적극적으로 참여하고 의료 전문가와 보다 효율적으로 상호 작용할 수 있습니다. 수많은 병원과 의료 기관은 웹 포털을 통해 환자에게 면역 검사 및 혈액 검사를 제공하여 병리학 실험실 등에 대한 접근성이 낮은 등 다양한 상황으로 인해 어려움을 겪는 사람들에게 간편하게 제공합니다.

따라서 디지털 건강 솔루션이나 치료 관리 기술이 시장 성장의 기회로 작용할 것으로 기대됩니다.

도전/ 제약

  • 약물과 관련된 부작용

면역 체계를 억제하는 약물은 천포창(PV)을 치료하여 자가면역 반응을 관리하는 데 사용됩니다. 이러한 약물은 PV를 관리하는 데 도움이 될 수 있지만 해로운 부작용이 있을 가능성도 있습니다. 약물과 사람에 따라 정확한 부작용은 달라질 수 있습니다. 각 환자의 치료는 고유한 병력과 동반 질환에 따라 맞춤화되어야 합니다. 환자는 가능한 최상의 치료를 받는 동안 최소한의 질병 활동만 겪을 수 있습니다. 물집 형성을 예방하도록 설계된 약물은 일반적으로 첫 번째 치료로 사용됩니다. 일반적으로 초기 단계에서 더 잘 작동합니다.

따라서 해당 약물로 인한 부작용은 시장 성장에 어려움을 줄 것으로 예상됩니다.

  • 엄격한 규제 지침

천포창을 포함한 수많은 의학적 장애의 진단, 치료 및 관리에 대한 조언 및 표준 제공은 규제 지침에 의해 용이해집니다. 피부과 또는 자가면역 질환에 초점을 맞춘 규제 기관 및 조직은 일반적으로 이러한 지침을 수립합니다. 천포창을 치료하는 데 사용되는 약물의 안전성, 효과 및 품질을 보장하기 위해 규제 기관은 이를 평가하고 승인할 수 있습니다.

의약품 허가 및 감독에 관해 합리적인 선택을 내리기 위해 임상 시험, 제조 절차, 부작용 보고 시스템으로부터 얻은 정보를 고려할 수 있습니다.     

따라서 엄격한 규제 지침이 시장 성장을 억제할 것으로 예상됩니다.

최근 개발 사항

  • 2023년 6월, AstraZeneca는 내성성 전신성 중증 근무력증(gMG) 및 항아세틸콜린 수용체(AChR) 항체 양성인 성인 환자의 치료를 위해 Soliris(eculizumab)가 중국에서 승인을 받았다고 발표했습니다. 중국에서 gMG 치료에 승인된 유일한 보체 억제제는 Soliris입니다. 3상 REGAIN 시험의 포괄적인 결과는 중국 국가의약품감독관리총국(NMPA)의 승인을 위한 기반이 되었습니다.
  • 2023년 1월, Merck & Co., Inc.는 FDA가 Merck의 항-PD-1 치료제인 KEYTRUDA를 수술적 절제 및 백금 기반 화학 요법에 따른 보조 요법을 위한 단일제로 승인했다고 발표했습니다. 이는 IB기(T2a 4센티미터[cm]), II기 또는 IIIA기 비소세포 폐암(NSCLC) 성인 환자를 위한 것입니다.

글로벌 천포창 Vulgaris 시장 범위

글로벌 천포창 심상성 시장은 진단 및 치료, 인구 유형, 최종 사용자 및 유통 채널로 세분화됩니다. 세그먼트 간의 성장은 틈새 시장 개발 및 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.

진단 및 치료

  • 진단
  • 치료

진단과 치료를 기준으로 시장은 진단과 치료로 세분화됩니다.

인구 유형

  • 소아과
  • 성인
  • 노인

인구 유형을 기준으로 시장은 소아, 성인, 노인으로 구분됩니다.

최종 사용자

  • 병원
  • 전문 클리닉
  • 연구 기관
  • 기타

최종 사용자를 기준으로 시장은 병원, 전문 병원, 연구소 등으로 구분됩니다.

유통 채널

  • 병원 약국
  • 소매 약국
  • 온라인 약국

유통 채널을 기준으로 시장은 병원 약국, 소매 약국, 온라인 약국으로 구분됩니다.

천포창 Vulgaris 시장

글로벌 천포창 Vulgaris 시장 지역 분석/통찰력

시장을 분석하고, 진단 및 치료, 인구 유형, 최종 사용자, 유통 채널별로 시장 규모 정보를 제공합니다.

The countries covered in this market report are U.S., Canada, and Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, and Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, and Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.

North America is expected to dominate due to the presence of key market players in the largest consumer market with high GDP. The U.S. is expected to grow due to the rise in technological advancement for pemphigus vulgaris.

The increasing investment in R&D and increasing adoption of personalized medicine for pemphigus vulgaris as an option for the formulation of treatment regimens are expected to boost the market growth. The U.S. dominates the North American region due to the strong presence of advanced technology providers such as Novartis AG, Amgen Inc., Merck & Co., Inc., AstraZeneca, and others. The Germany dominates the Europe region due to the increasing demand from emerging markets and the expansion of healthcare industries. China dominates the Asia-Pacific region due to an increase in healthcare expenditure.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

천포창 Vulgaris 시장

Competitive Landscape and Global Pemphigus Vulgaris Market Share Analysis

Global pemphigus vulgaris market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the global pemphigus vulgaris market.

글로벌 천포창 시장의 주요 기업으로는 Sanofi, Regeneron Pharmaceuticals Inc., Fresenius Kabi AG, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., RAKSHIT DRUGS PVT. LTD, F. Hoffmann-La Roche Ltd, Pfizer Inc., Celltrion Healthcare Co., Ltd., AbbVie Inc., Novartis AG, Amgen Inc., Merck & Co., Inc., AstraZeneca, Teva Pharmaceutical Industries Ltd, Lilly, Zydus Group, GSK plc 등이 있습니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER FIVE FORCES

4.3 PATENT ANALYSIS

4.4 PATIENT FLOW DIAGRAM

4.5 KEY PRICING STRATEGIES

4.6 FUTURE THERAPIES

4.7 KEY PATIENT ENROLLMENT STRATEGIES

5 PIPELINE ANALYSIS

6 EPIDEMIOLOGY

7 INDUSTRY INSIGHTS

8 GLOBAL PEMPHIGUS VULGARIS MARKET: REGULATIONS

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS

9.1.2 GROWING SUPPORT OF NGOS FOR THE AFFECTED PATIENTS

9.1.3 AWARENESS REGARDING THE DISEASE

9.2 RESTRAINTS

9.2.1 STRICT REGULATORY GUIDELINES

9.2.2 HIGH TREATMENT COSTS

9.3 OPPORTUNITIES

9.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE

9.3.2 INCREASING HEALTHCARE FACILITIES

9.3.3 DIGITAL HEALTH TECHNOLOGIES FOR TREATMENT MANAGEMENT

9.4 CHALLENGES

9.4.1 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS

9.4.2 REIMBURSEMENT AND COVERAGE POLICIES

10 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT

10.1 OVERVIEW

10.2 TREATMENT

10.2.1 MEDICATIONS, BY TYPE

10.2.1.1 CORTICOSTEROIDS

10.2.1.2 STEROID- SPARING IMMUNOSUPPRESSANT DRUGS

10.2.1.2.1 AZATHIOPRINE

10.2.1.2.2 MYCOPHENALATE MOFETIL

10.2.1.2.3 METHOTREXATE

10.2.1.2.4 CYCLOPHOSPHAMIDE

10.2.1.2.5 MIZORIBINE

10.2.1.2.6 OTHERS

10.2.1.3 ANTI- INFLAMMATORY AGENTS

10.2.1.3.1 DIAMINODYPHENYL SULFONE

10.2.1.3.2 TETRACYCLINE

10.2.1.3.3 OTHERS

10.2.1.4 BIOLOGICS

10.2.1.5 INTRAVENOUS IMMUNOGLOBULIN

10.2.1.6 ANTIBIOTICS

10.2.1.7 ANTIFUNGALS

10.2.1.8 ANTIVIRALS

10.2.1.9 OTHER MEDICATIONS

10.2.2 MEDICATIONS, BY ROUTE OF ADMINISTRATION

10.2.2.1 ORAL

10.2.2.2 TOPICAL

10.2.2.3 PARENTERAL

10.2.2.4 OTHERS

10.2.3 MEDICATIONS, BY DRUG TYPE

10.2.3.1 GENERIC

10.2.3.2 BRANDED

10.3 DIAGNOSIS

10.3.1 SKIN BIOPSY

10.3.2 BLOOD TEST

10.3.3 ENDOSCOPY

11 GLOBAL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE

11.1 OVERVIEW

11.2 ADULTS

11.3 GERIATRIC

11.4 PEDIATRIC

12 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS

12.3 SPECIALTY CLINICS

12.4 RESEARCH INSTITUTES

12.5 OTHERS

13 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 HOSPITALS PHARMACY

13.3 RETAIL PHARMACY

13.4 ONLINE PHARMACY

14 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION

14.1 OVERVIEW

14.2 NORTH AMERICA

14.2.1 U.S.

14.2.2 CANADA

14.2.3 MEXICO

14.3 EUROPE

14.3.1 GERMANY

14.3.2 U.K.

14.3.3 FRANCE

14.3.4 ITALY

14.3.5 SPAIN

14.3.6 SWITZERLAND

14.3.7 TURKEY

14.3.8 RUSSIA

14.3.9 BELGIUM

14.3.10 NETHERLANDS

14.3.11 REST OF EUROPE

14.4 ASIA-PACIFIC

14.4.1 CHINA

14.4.2 INDIA

14.4.3 SOUTH KOREA

14.4.4 MALAYSIA

14.4.5 JAPAN

14.4.6 AUSTRALIA

14.4.7 SINGAPORE

14.4.8 THAILAND

14.4.9 INDONESIA

14.4.10 PHILIPPINES

14.4.11 REST OF ASIA-PACIFIC

14.5 SOUTH AMERICA

14.5.1 BRAZIL

14.5.2 ARGENTINA

14.5.3 REST OF SOUTH AMERICA

14.6 MIDDLE EAST AND AFRICA

14.6.1 SAUDI ARABIA

14.6.2 EGYPT

14.6.3 U.A.E.

14.6.4 SOUTH AFRICA

14.6.5 ISRAEL

14.6.6 REST OF MIDDLE EAST AND AFRICA

15 GLOBAL PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: GLOBAL

15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

15.3 COMPANY SHARE ANALYSIS: EUROPE

15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

16 SWOT ANALYSIS

17 COMPANY PROFILE

17.1 ABBVIE INC.

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENTS

17.2 MERCK & CO., INC.,

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENT

17.3 SANOFI

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENT

17.4 REGENERON PHARMACEUTICALS INC.

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENT

17.5 NOVARTIS AG

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENT

17.6 AMGEN INC.

17.6.1 COMPANY SNAPSHOT

17.6.2 REVENUE ANALYSIS

17.6.3 PRODUCT PORTFOLIO

17.6.4 RECENT DEVELOPMENTS

17.7 ASTRAZENECA

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 COMPANY SHARE ANALYSIS

17.7.4 PRODUCT PORTFOLIO

17.7.5 RECENT DEVELOPMENTS

17.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

17.8.1 COMPANY SNAPSHOT

17.8.2 REVENUE ANALYSIS

17.8.3 PRODUCT PORTFOLIO

17.8.4 RECENT DEVELOPMENT

17.9 CELLTRION HEALTHCARE CO., LTD

17.9.1 COMPANY SNAPSHOT

17.9.2 REVENUE ANALYSIS

17.9.3 PRODUCT PORTFOLIO

17.9.4 RECENT DEVELOPMENTS

17.1 F. HOFFMANN- LA ROCHE LTD.

17.10.1 COMPANY SNAPSHOT

17.10.2 REVENUE ANALYSIS

17.10.3 PRODUCT PORTFOLIO

17.10.4 RECENT DEVELOPMENT

17.11 FRESENIUS KABI AG

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE ANALYSIS

17.11.3 PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENT

17.12 GSK PLC

17.12.1 COMPANY SNAPSHOT

17.12.2 REVENUE ANALYSIS

17.12.3 PRODUCT PORTFOLIO

17.12.4 RECENT DEVELOPMENT

17.13 JOHNSON & JOHNSON SERVICES, INC.

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 COMPANY SHARE ANALYSIS

17.13.4 PRODUCT PORTFOLIO

17.13.5 RECENT DEVELOPMENT

17.14 LILLY

17.14.1 COMPANY SNAPSHOT

17.14.2 REVENUE ANALYSIS

17.14.3 PRODUCT PORTFOLIO

17.14.4 RECENT DEVELOPMENT

17.15 PFIZER INC.

17.15.1 COMPANY SNAPSHOT

17.15.2 REVENUE ANALYSIS

17.15.3 PRODUCT PORTFOLIO

17.15.4 RECENT DEVELOPMENT

17.16 RAKSHIT DRUGS PVT. LTD

17.16.1 COMPANY SNAPSHOT

17.16.2 PRODUCT PORTFOLIO

17.16.3 RECENT DEVELOPMENT

17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD

17.17.1 COMPANY SNAPSHOT

17.17.2 REVENUE ANALYSIS

17.17.3 PRODUCT PORTFOLIO

17.17.4 RECENT DEVELOPMENT

17.18 ZYDUS GROUP

17.18.1 COMPANY SNAPSHOT

17.18.2 REVENUE ANALYSIS

17.18.3 PRODUCT PORTFOLIO

17.18.4 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

표 목록

TABLE 1 GLOBAL PEMPHIGUS VULGARIS MARKET, PATENT ANALYSIS

TABLE 2 GLOBAL PEMPHIGUS VULGARIS MARKET, PIPELINE ANALYSIS

TABLE 3 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 4 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 6 GLOBAL STEROID- SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 7 GLOBAL ANTI- INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 8 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 9 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 10 GLOBAL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 11 GLOBAL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 12 GLOBAL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 13 GLOBAL ADULTS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 GLOBAL GERIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 GLOBAL PEDIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 17 GLOBAL HOSPITALS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 GLOBAL SPECIALTY CLINICS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 GLOBAL RESEARCH INSTITUTES IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 GLOBAL OTHERS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 22 GLOBAL HOSPITALS PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 GLOBAL RETAIL PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 GLOBAL ONLINE PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 27 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 28 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 29 NORTH AMERICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 30 NORTH AMERICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 31 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 32 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 33 NORTH AMERICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 34 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 35 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 36 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 37 U.S. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 38 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 39 U.S. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 40 U.S. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 41 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 42 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 43 U.S. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 44 U.S. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 45 U.S. PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 46 U.S. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 47 CANADA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 48 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 49 CANADA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 50 CANADA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 51 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 52 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 53 CANADA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 54 CANADA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 55 CANADA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 56 CANADA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 57 MEXICO PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 58 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 59 MEXICO STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 60 MEXICO ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 61 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 62 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 63 MEXICO DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 64 MEXICO PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 65 MEXICO PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 66 MEXICO PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 67 EUROPE PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 68 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 69 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 70 EUROPE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 71 EUROPE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 72 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 73 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 74 EUROPE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 75 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 76 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 77 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 78 GERMANY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 79 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 80 GERMANY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 81 GERMANY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 82 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 83 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 84 GERMANY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 85 GERMANY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 86 GERMANY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 87 GERMANY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 88 U.K. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 89 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 90 U.K. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 91 U.K. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 92 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 93 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 94 U.K. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 95 U.K. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 96 U.K. PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 97 U.K. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 98 FRANCE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 99 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 100 FRANCE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 101 FRANCE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 102 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 103 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 104 FRANCE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 105 FRANCE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 106 FRANCE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 107 FRANCE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 108 ITALY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 109 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 110 ITALY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 111 ITALY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 112 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 113 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 114 ITALY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 115 ITALY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 116 ITALY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 117 ITALY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 118 SPAIN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 119 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 120 SPAIN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 121 SPAIN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 122 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 123 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 124 SPAIN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 125 SPAIN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 126 SPAIN PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 127 SPAIN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 128 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 129 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 130 SWITZERLAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 131 SWITZERLAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 132 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 133 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 134 SWITZERLAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 135 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 136 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 137 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 138 TURKEY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 139 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 140 TURKEY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 141 TURKEY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 142 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 143 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 144 TURKEY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 145 TURKEY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 146 TURKEY PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 147 TURKEY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 148 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 149 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 150 RUSSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 151 RUSSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 152 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 153 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 154 RUSSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 155 RUSSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 156 RUSSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 157 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 158 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 159 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 160 BELGIUM STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 161 BELGIUM ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 162 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 163 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 164 BELGIUM DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 165 BELGIUM PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 166 BELGIUM PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 167 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 168 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 169 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 170 NETHERLANDS STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 171 NETHERLANDS ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 172 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 173 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 174 NETHERLANDS DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 175 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 176 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 177 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 178 REST OF EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 179 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 180 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 181 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 182 ASIA-PACIFIC STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 183 ASIA-PACIFIC ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 184 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 185 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 186 ASIA-PACIFIC DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 187 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 188 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 189 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 190 CHINA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 191 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 192 CHINA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 193 CHINA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 194 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 195 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 196 CHINA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 197 CHINA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 198 CHINA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 199 CHINA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 200 INDIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 201 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 202 INDIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 203 INDIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 204 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 205 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 206 INDIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 207 INDIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 208 INDIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 209 INDIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 210 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 211 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 212 SOUTH KOREA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 213 SOUTH KOREA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 214 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 215 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 216 SOUTH KOREA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 217 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 218 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 219 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 220 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 221 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 222 MALAYSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 223 MALAYSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 224 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 225 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 226 MALAYSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 227 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 228 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 229 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 230 JAPAN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 231 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 232 JAPAN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 233 JAPAN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 234 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 235 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 236 JAPAN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 237 JAPAN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 238 JAPAN PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 239 JAPAN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 240 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 241 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 242 AUSTRALIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 243 AUSTRALIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 244 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 245 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 246 AUSTRALIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 247 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 248 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 249 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 250 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 251 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 252 SINGAPORE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 253 SINGAPORE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 254 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 255 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 256 SINGAPORE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 257 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 258 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 259 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 260 THAILAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 261 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 262 THAILAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 263 THAILAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 264 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 265 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 266 THAILAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 267 THAILAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 268 THAILAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 269 THAILAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 270 INDONESIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 271 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 272 INDONESIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 273 INDONESIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 274 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 275 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 276 INDONESIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 277 INDONESIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 278 INDONESIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 279 INDONESIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 280 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 281 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 282 PHILIPPINES STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 283 PHILIPPINES ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 284 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 285 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 286 PHILIPPINES DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 287 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 288 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 289 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 290 REST OF ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 291 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 292 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 293 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 294 SOUTH AMERICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 295 SOUTH AMERICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 296 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 297 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 298 SOUTH AMERICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 299 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 300 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 301 BRAZIL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 302 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 303 BRAZIL STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 304 BRAZIL ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 305 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 306 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 307 BRAZIL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 308 BRAZIL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 309 BRAZIL PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 310 BRAZIL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 311 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 312 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 313 ARGENTINA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 314 ARGENTINA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 315 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 316 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 317 ARGENTINA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 318 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 319 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 320 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 321 REST OF SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 322 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 323 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 324 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 325 MIDDLE EAST AND AFRICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 326 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 327 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 328 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 329 MIDDLE EAST AND AFRICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 330 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 331 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 332 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 333 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 334 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 335 SAUDI ARABIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 336 SAUDI ARABIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 337 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 338 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 339 SAUDI ARABIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 340 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 341 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 342 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 343 EGYPT PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 344 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 345 EGYPT STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 346 EGYPT ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 347 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 348 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 349 EGYPT DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 350 EGYPT PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 351 EGYPT PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 352 EGYPT PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 353 U.A.E. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 354 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 355 U.A.E. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 356 U.A.E. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 357 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 358 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 359 U.A.E. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 360 U.A.E. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 361 U.A.E. PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 362 U.A.E. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 363 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 364 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 365 SOUTH AFRICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 366 SOUTH AFRICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 367 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 368 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 369 SOUTH AFRICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 370 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 371 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 372 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 373 ISRAEL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

TABLE 374 ISRAEL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 375 ISRAEL STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 376 ISRAEL ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 377 ISRAEL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 378 ISRAEL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 379 ISRAEL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 380 ISRAEL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 381 ISRAEL PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 382 ISRAEL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 383 REST OF MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION)

그림 목록

FIGURE 1 GLOBAL PEMPHIGUS VULGARIS MARKET: SEGMENTATION

FIGURE 2 GLOBAL PEMPHIGUS VULGARIS MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL PEMPHIGUS VULGARIS MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL PEMPHIGUS VULGARIS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL PEMPHIGUS VULGARIS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL PEMPHIGUS VULGARIS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL PEMPHIGUS VULGARIS MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 GLOBAL PEMPHIGUS VULGARIS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL PEMPHIGUS VULGARIS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL PEMPHIGUS VULGARIS MARKET: SEGMENTATION

FIGURE 11 THE EMERGING TREATMENT OPTIONS FOR THE PEMPHIGUS VULGARISIS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL PEMPHIGUS VULGARIS MARKET FROM 2023 TO 2030

FIGURE 12 THE DIAGNOSIS AND TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PEMPHIGUS VULGARIS MARKET IN 2023 AND 2030

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL PEMPHIGUS VULGARIS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PEMPHIGUS VULGARIS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 15 PATIENT FLOW DESCRIPTION OF PEMPHIGUS VULGARIS:-

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL PEMPHIGUS VULGARIS MARKET

FIGURE 17 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2022

FIGURE 18 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2023-2030 (USD MILLION)

FIGURE 19 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2023-2030)

FIGURE 20 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE

FIGURE 21 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2022

FIGURE 22 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2023-2030 (USD MILLION)

FIGURE 23 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, CAGR (2023-2030)

FIGURE 24 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 25 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, 2022

FIGURE 26 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 27 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 28 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, LIFELINE CURVE

FIGURE 29 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 30 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 31 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 32 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 33 GLOBAL PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022)

FIGURE 34 GLOBAL PEMPHIGUS VULGARIS MARKET: BY REGION (2022)

FIGURE 35 GLOBAL PEMPHIGUS VULGARIS MARKET: BY REGION (2023 & 2030)

FIGURE 36 GLOBAL PEMPHIGUS VULGARIS MARKET: BY REGION (2022 & 2030)

FIGURE 37 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT (2023 & 2030)

FIGURE 38 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022)

FIGURE 39 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022)

FIGURE 40 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 41 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 42 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT (2023-2030)

FIGURE 43 EUROPE PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022)

FIGURE 44 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022)

FIGURE 45 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 46 EUROPE PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 47 EUROPE PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030)

FIGURE 48 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022)

FIGURE 49 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022)

FIGURE 50 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 51 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 52 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030)

FIGURE 53 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022)

FIGURE 54 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022)

FIGURE 55 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 56 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 57 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030)

FIGURE 58 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022)

FIGURE 59 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022)

FIGURE 60 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 61 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 62 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030)

FIGURE 63 GLOBAL PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%)

FIGURE 64 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%)

FIGURE 65 EUROPE PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%)

FIGURE 66 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

尋常性天疱瘡の市場規模は、2030年までに6億7,732万米ドルに達すると予想されています。
尋常性天疱瘡市場の成長率は2030年までに8.2%です。
尋常性天疱瘡に対する新たな治療法やアプローチは、尋常性天疱瘡市場の成長を牽引しています。
尋常性天疱瘡市場の主要企業は、サノフィ、リジェネロン・ファーマシューティカルズ社、フレゼニウス・カビ社、ベーリンガーインゲルハイム・インターナショナル社、ジョンソン・エンド・ジョンソン・サービス社、ラクシット・ドラッグス社、F. ホフマン・ラ・ロシュ社、ファイザー社、セルトリオン・ヘルスケア社、アッヴィ社、ノバルティス社、アムジェン社、メルク社、アストラゼネカ社、テバ・ファーマシューティカル・インダストリーズ社、リリー社、ザイダス・グループ、GSK plc です。
診断と治療、人口タイプ、エンドユーザー、流通チャネルは、尋常性天疱瘡の市場調査の基礎となる要素です。
Testimonial